Is QGEN a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on QIAstat-Dx syndromic testing, with revenue (q1 2026) at ~$492M. The bear case rests on quantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. Analysts covering it are spread from $36.00 to $49.47, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. QuantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $36.00, -14.3% from the $42.00 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

QIAstat-Dx syndromic testing. QIAstat-Dx, QIAGEN's cartridge-based syndromic panel system, has been a standout with strong constant-currency growth and heavy new-instrument placements. The most optimistic analyst target on QGEN is $49.47, +17.8% from the $42.00 price. That figure is only reachable if this thesis works close to its best case.

QuantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings. A large share of revenue tracks academic, pharma, and life-sciences research budgets, which softened in the U.S. and remain sensitive to funding cycles. Roughly half of sales are outside the U.S., so currency moves materially affect reported results (reported growth outpaced constant-currency growth in Q1 2026). QIAGEN competes against much larger, better-capitalized rivals, and guidance cuts have shown the top line is vulnerable to demand shocks. Integration of acquisitions like Parse Biosciences carries execution risk. The most pessimistic published target is $36.00, -14.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

QIAGEN makes the consumables and instruments labs use to collect, stabilize, purify, and analyze DNA and RNA, then extends into molecular diagnostics through platforms like QIAstat

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (QIAstat-Dx syndromic testing) stalling in the reported numbers rather than in the narrative, the risk above (quantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

QIAGEN provides sample and assay technologies for molecular testing. It sells consumables and instruments that collect, purify, and analyze DNA and RNA, plus molecular diagnostic platforms like QIAstat-Dx and QuantiFERON used by labs in diagnostics, research, and pharma.

QIAGEN N.V. is legally domiciled in the Netherlands with German roots, but its shares trade on the NYSE under QGEN (and also in Frankfurt). It is a large, established multinational, not a foreign shell or thinly traded OTC listing.

Reported sales rose about 2 percent to roughly $492 million, but constant-currency sales fell about 1 percent as weaker QuantiFERON and cautious U.S. Life Sciences demand offset strong Sample technologies and QIAstat-Dx growth. Adjusted EPS came in around the low end of guidance.